PRNewswire/ — Leigh Steinberg, the legendary sports agent and inspiration for the film “Jerry Maguire,” is joining retired NFL players in calling attention to the need for greater participation in Alzheimer’s clinical trials.
Steinberg is set to speak at the “Huddle Up for New Alzheimer’s Treatments” event on May 5 in Westlake Village, Calif., where he will team with campaign ambassadors Solomon Wilcots and Ron Pitts as well as Dr. Omid Rabbani, a Ventura County neurologist who is an investigator in Axovant Sciences’ MINDSET study. Topics covered at the event will include Alzheimer’s disease, the importance of clinical research participation and the MINDSET study. Dr. Rabbani will also offer free memory screenings. read more
A New Study Reveals Abnormally Low Blood Flow To NFL Players’ Brains
With concern growing in recent years about the long-term impact of head trauma in the NFL, a new study has revealed abnormal areas of low blood flow in the brains of current and retired professional football players. Researchers made their discovery using sophisticated neuroimaging and analytics, according to the study, published in the Journal of Alzheimer’s Disease .With concern growing in recent years about the long-term impact of head trauma in the NFL, a new study has revealed abnormal areas of low blood flow in the brains of current and retired professional football players. read nore
FDA approves ORFADIN® (nitisinone) Oral Suspension
Swedish Orphan Biovitrum AB (Sobi), an international specialty healthcare company dedicated to rare diseases, today announced that the Food and Drug Administration (FDA) has approved ORFADIN® Oral Suspension for the treatment of Hereditary Tyrosinemia Type 1 (HT-1). ORFADIN is indicated for use in combination with dietary restriction of tyrosine and phenylalanine.
This new formulation is an alternative to the capsules and provides an additional option for infants and small children. ORFADIN Oral Suspension comes in a 4 mg/mL dose. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney complications and can be fatal if untreated. Before pharmacological treatment was available, less than one third of infants diagnosed with HT-1 before two months of age lived past their second birthday.1 Treatment with ORFADIN combined with dietary restriction of tyrosine and phenylalanine plus more widespread newborn screening leading to early diagnosis has greatly improved outcomes for HT-1 patients.2
Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases
Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACTTM AdmiralTM drug-coated balloon (DCB) with several new presentations that showed durable and consistent clinical outcomes in the most challenging patients with peripheral artery disease (PAD). The new data, presented at the 2016 Charing Cross Symposium in London, included the one-year results from the chronic total occlusion imaging cohort from the IN.PACT Global Study and the two-year gender and diabetic subgroup analyses from the pivotal IN.PACT SFA Trial. read more
Sensorcaine-MPF (bupivacaine HCl) by Fresenius Kabi: Recall – Presence of Particulate Matter
Fresenius Kabi USA announced today it is voluntarily recalling a single lot (Lot Number 6111504; Product Code 470237) of Sensorcaine-MPF (bupivacaine HCl) Injection, USP, 0.75%, 7.5 mg/mL, 30 mL fill in a 30 mL vial. The recall is being performed to the user level due to visible particulate matter characterized as glass observed by the company during inspection of reserve samples. read more
Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have a New Treatment Option as LONSURF® (trifluridine/tipiracil) Receives EU Approval
SURESNES, France–(BUSINESS WIRE)–Servier today announced that the European Commission (EC) has granted marketing authorization for LONSURF® (trifluridine/tipiracil), formerly known as TAS-102, in the European Union (EU) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. LONSURF is an oral anticancer drug, comprising the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. read more
Life Science Startup Company Strekin AG Announces the Launch of a Phase 2 Clinical Study of STR001 as a Potential New Treatment for Hearing Loss
At the Sachs CEO forum in Zürich, Strekin AG announced the launch of a Phase 2 clinical study of its lead drug candidate, STR001, to preserve residual hearing in patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 study is currently recruiting patients in Germany and France. STR001 is administered directly into the middle ear at the time of surgery. “Despite advances in cochlear implant technology, a risk of CI surgery is the loss of residual hearing. Therapies, such as STR001, that have the potential to prevent this undesired effect, could be very beneficial to patients,” said Prof Arneborg Ernst (UKB Berlin), the Clinical Lead Investigator of the trial.
United Therapeutics Corporation To Present At Deutsche Bank 41st Annual Health Care Conference
The presentation will take place on Thursday, May 5, 2016, at 10:00 a.m. Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the “Investors” tab in the “Events and Presentations” section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the presentation ends and can be accessed at the same location for 90 days. [uthr-g]
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening diseases.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-deutsche-bank-41st-annual-health-care-conference-300258181.html
SOURCE United Therapeutics Corporation
CONTACT: James Edgemond, (301) 608-9292, email@example.com
Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer
Overall Survival data from the Phase III study meets endpoint and demonstrates non-inferiority favoring Paclical/Apealea; will form basis for application seeking marketing approval in the United States anticipated for the end of 2016/2017.
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer. These preliminary results showed non-inferiority between the two treatment groups: Paclical/Apealea in combination with carboplatin versus Taxol in combination with carboplatin. In fact, the overall survival in patients completing 6 treatment cycles was 25.7 months in patients that had received the Paclical/Apealea combination compared to 24.8 months in patients that had received the Taxol combination. For more information, visit the Oasmia website, http://www.oasmia.com